Related Experiment Video
Updated: Jul 18, 2026
11:20
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
Rituximab in subacute sclerosing panencephalitis
Luigi Titomanlio1, Najla Soyah, Valérie Guerin
1Department of Child Neurology, Robert Debré Hospital, Paris VII University, Paris, France. luigi.titomanlio@rdb.aphp.fr
Summary
Subacute sclerosing panencephalitis (SSPE) is a fatal measles virus brain infection. Carbamazepine improved quality of life, but measles vaccination remains the only preventative solution for this rare childhood neurological disorder.
Area of Science:
- Neurology
- Virology
- Immunology
Background:
- Subacute sclerosing panencephalitis (SSPE) is a progressive, fatal neurological disease in children and adolescents.
- It results from a persistent measles virus infection in the brain, with no current effective treatments.
- The underlying pathophysiology of SSPE remains largely unelucidated.
Observation:
- The potential role of humoral immunity in SSPE pathogenesis was investigated.
- A single patient received anti-CD20 antibodies on a compassionate basis.
- Disease progression continued despite anti-CD20 antibody treatment, prompting re-evaluation of B cell involvement.
Findings:
- Carbamazepine demonstrated utility in enhancing the quality of life for the treated patient.
- This suggests carbamazepine could be considered a first-line symptomatic treatment option.
- Measles vaccination is currently the sole effective measure for preventing SSPE.
Implications:
- Further research is needed to understand the precise role of B cells and humoral immunity in SSPE.
- Carbamazepine may offer a valuable therapeutic option for managing SSPE symptoms and improving patient well-being.
- Strengthening global measles vaccination efforts is critical for the primary prevention of SSPE.
